{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:36:31Z","timestamp":1788215791100,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Antithrombotic therapy prevents adverse ischemic events following acute ischemic stroke (AIS). Intravenous tirofiban provides desirable antiplatelet effects, especially in patients who are vulnerable to neurological deterioration (ND).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM:<\/jats:title>\n                    <jats:p>The aim of the study was to test the hypothesis that intravenous administration of tirofiban, initiated within 24 h of ictus and continued for consecutive 72 h, would be more effective than aspirin in reducing the risk of ND within 72 h of enrollment among patients with potentially atherothrombotic ischemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The Safety and Efficacy of Tirofiban in Preventing Neurological Deterioration in Acute Ischemic Stroke (TREND) trial is an investigator-initiated, multicenter, prospective, randomized, open-label, masked endpoint study. Its eligibility criteria included AIS secondary to potential atherosclerosis, a National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 20 points, ineligibility for recanalization therapy, and administration within 24 h postsymptom onset. Randomization was performed at a 1:1 ratio to allocate 420 patients into two groups to receive an intravenous tirofiban bridge to oral antiplatelet drugs or direct oral antiplatelet drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OUTCOMES:<\/jats:title>\n                    <jats:p>The primary outcome is the proportion of patients with a \u22654-point increase in NIHSS score within 72 h of intervention compared to the score at enrollment. The key secondary outcomes include changes in NIHSS score, modified Rankin scale (mRS) score at 90 days, and dichotomized mRS scores (0\u20132 vs. 3\u20136 and 0\u20131 vs. 2\u20136) at 90 days. The safety variables are symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, and systemic hemorrhage within 72 h after randomization and 90-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The TREND trial may identify the suitability of intravenous tirofiban as a routine clinical strategy to prevent ND in patients with AIS within 24 h of the onset of symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>http:\/\/www.clinicaltrials.gov (identifier: NCT04491695).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/bc.bc_93_23","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T04:04:40Z","timestamp":1719374680000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of tirofiban in preventing neurological deterioration in acute ischemic stroke (TREND): Protocol for an investigator-initiated, multicenter, prospective, randomized, open-label, masked endpoint trial"],"prefix":"10.4103","volume":"10","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunming","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"},{"name":"Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the TREND Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","article-title":"Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke:A systematic review with pathophysiological implications","volume":"86","author":"Seners","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/bc.bc_68_21","article-title":"Neurological deterioration and computed tomography perfusion changes with increased time to peak in lacunar stroke","volume":"8","author":"Farooqui","year":"2022","journal-title":"Brain Circ"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0967-5868(02)00325-9","article-title":"Progression in acute ischemic stroke:Frequency, risk factors and prognosis","volume":"10","author":"Sumer","year":"2003","journal-title":"J Clin Neurosci"},{"key":"R4-20240830","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221147743","article-title":"Early neurological deterioration in patients with acute ischemic stroke:A prospective multicenter cohort study","volume":"16","author":"Liu","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1179\/1743132815Y.0000000024","article-title":"Predictors of neurological deterioration during hospitalization:Results from the Chinese intracranial atherosclerosis (CICAS) study","volume":"37","author":"Ma","year":"2015","journal-title":"Neurol Res"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/STROKEAHA.113.003508","article-title":"Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China:The Chinese intracranial atherosclerosis (CICAS) study","volume":"45","author":"Wang","year":"2014","journal-title":"Stroke"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10072-022-06446-5","article-title":"Multiple chronic lacunes predicting early neurological deterioration and long-term functional outcomes according to TOAST classification in acute ischemic stroke","volume":"44","author":"Lee","year":"2023","journal-title":"Neurol Sci"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2147\/NDT.S365758","article-title":"Predictors of early neurological deterioration and functional outcome in acute ischemic stroke:The importance of large artery disease, hyperglycemia and inflammatory blood biomarkers","volume":"18","author":"Sabir Rashid","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"e2178","DOI":"10.1212\/WNL.0000000000010603","article-title":"Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack","volume":"95","author":"Park","year":"2020","journal-title":"Neurology"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke:2019 update to the 2018 guidelines for the early management of acute ischemic stroke:A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/bc.bc_56_22","article-title":"Branch atheromatous disease and treatment","volume":"8","author":"Duan","year":"2022","journal-title":"Brain Circ"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/bc.bc_75_21","article-title":"Aspirin resistance and blood biomarkers in predicting ischemic stroke recurrence:An exploratory study","volume":"8","author":"Dash","year":"2022","journal-title":"Brain Circ"},{"key":"R15-20240830","first-page":"515","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibitor tirofiban in acute ischemic stroke","volume":"79","author":"Yang","year":"2019","journal-title":"Drugs"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","article-title":"Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions:The EVEREST trial","volume":"47","author":"Bolognese","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/STROKEAHA.110.599662","article-title":"Safety of tirofiban in acute ischemic stroke:The SaTIS trial","volume":"42","author":"Siebler","year":"2011","journal-title":"Stroke"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/STROKEAHA.119.026240","article-title":"Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis","volume":"50","author":"Wu","year":"2019","journal-title":"Stroke"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/STROKEAHA.116.014413","article-title":"Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients","volume":"47","author":"Li","year":"2016","journal-title":"Stroke"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"107867","DOI":"10.1016\/j.clineuro.2023.107867","article-title":"Safety and efficacy of tirofiban in the management of stroke:A systematic review and meta-analysis of randomized controlled trials","volume":"232","author":"Al-Salihi","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa2214299","article-title":"Tirofiban for stroke without large or medium-sized vessel occlusion","volume":"388","author":"Zi","year":"2023","journal-title":"N Engl J Med"},{"key":"R23-20240830","first-page":"666","article-title":"Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018","volume":"51","year":"2018","journal-title":"Chin J Neurol"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack:A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/HJH.0000000000000675","article-title":"Blood pressure variability and the development of early neurological deterioration following acute ischemic stroke","volume":"33","author":"Chung","year":"2015","journal-title":"J Hypertens"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1212\/01.wnl.0000326064.42186.7e","article-title":"High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke","volume":"71","author":"Castellanos","year":"2008","journal-title":"Neurology"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00415-008-0820-z","article-title":"Acute stroke unit care and early neurological deterioration in ischemic stroke","volume":"255","author":"Roquer","year":"2008","journal-title":"J Neurol"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/bc.bc_22_23","article-title":"Stroke prevention and intracranial hemorrhage risk in atrial fibrillation management:A mini review","volume":"9","author":"Roychoudhury","year":"2023","journal-title":"Brain Circ"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.030","article-title":"Intracranial atherosclerosis in Chinese young adult stroke patients","volume":"23","author":"Niu","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/bc.bc_36_22","article-title":"Carotid atherosclerotic disease:A systematic review of pathogenesis and management","volume":"8","author":"Bir","year":"2022","journal-title":"Brain Circ"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000076161","article-title":"Progressing stroke:Towards an internationally agreed definition","volume":"17","author":"Birschel","year":"2004","journal-title":"Cerebrovasc Dis"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.12.003","article-title":"The ischemic stroke predictive risk score predicts early neurological deterioration","volume":"25","author":"Kim","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/0366-6999.222343","article-title":"Early neurological deterioration after recanalization treatment in patients with acute ischemic stroke:A retrospective study","volume":"131","author":"Zhang","year":"2018","journal-title":"Chin Med J (Engl)"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000113732","article-title":"Steno-occlusive arterial disease and early neurological deterioration in acute ischemic stroke","volume":"25","author":"Ois","year":"2008","journal-title":"Cerebrovasc Dis"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_93_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:26Z","timestamp":1787067506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_93_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_93_23","relation":{},"ISSN":["2394-8108","2455-4626"],"issn-type":[{"value":"2394-8108","type":"print"},{"value":"2455-4626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-10-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}